CN115956670A

CN115956670A - Composition and preparation for relieving visual fatigue, preparation method and application

Info

Publication number: CN115956670A
Application number: CN202111187925.8A
Authority: CN
Inventors: 李秀萍; 吴名草; 沈旭丹; 温迎雨; 王晶; 沈振宇; 郁星; 龚海燕; 陈盛君
Original assignee: Jiangyin Tianjiang Pharmaceutical Co Ltd
Current assignee: Jiangyin Tianjiang Pharmaceutical Co Ltd
Priority date: 2021-10-12
Filing date: 2021-10-12
Publication date: 2023-04-14

Abstract

The invention belongs to the field of functional foods, and particularly relates to a composition for relieving visual fatigue, a preparation method and application. The composition for relieving the asthenopia comprises, by weight, 1-5 parts of wolfberry powder, 0-5 parts of cassia seed powder, 0-5 parts of chrysanthemum powder, 0-5 parts of lutein substances, 0-5 parts of zeaxanthin, 0-1 part of biological food preservatives, 10-50 parts of a premix and 20-100 parts of water, wherein the premix comprises 10-50 parts of anthocyanin substances, 0-5 parts of natural carotene and 0-20 parts of prebiotics, and the composition is a combination of medicinal and edible medicinal materials and new food raw materials, is natural and healthy, can effectively relieve the asthenopia and solves the problem that the existing product is only improved aiming at a single disease. The preparation containing the composition provided by the invention has various dosage forms, is convenient to eat and is easy to carry.

Description

Composition and preparation for relieving visual fatigue, preparation method and application

Technical Field

The invention belongs to the field of eye function foods, and particularly relates to a composition for relieving visual fatigue, a preparation method and application.

Background

Asthenopia refers to a complex manifestation of excessive visual hypofunction and corresponding physical discomfort symptoms caused by excessive fixation, which is not an independent ophthalmic disease, but a syndrome interacting with systemic organic factors and psychological (mental) factors, belonging to the category of psychology and medicine. Visual fatigue is generally manifested in three aspects: (1) ocular aspect: soreness and distending pain of the eyes, photophobia, lacrimation, itching, dryness and dampness of the eyes, spasm of eye muscles, etc.; (2) visual aspect: distant vision or near vision are unclear, temporary vision is degraded, lines are easy to be wrongly read when characters are read, lines are blurred and double images are generated, foreign body sensation is caused, and the like; (3) systemic symptoms: headache, dizziness, soreness and pain of neck and shoulder, lethargy, debilitation, vexation, restlessness, irritability, difficulty in concentrating attention, and limb numbness, nausea, emesis, cardiopalmus, insomnia, hypomnesis, etc. in severe cases. The visual fatigue can cause the study disorder of teenagers and children, reduce the working efficiency of adults and directly influence the work and life of people. The repeated appearance of asthenopia for a long time may cause various eye diseases, such as dry eye syndrome, ametropia, VDT syndrome, computer vision syndrome, etc., and aggravate the occurrence of age-related eye diseases. Therefore, the cause, pathogenesis and corresponding preventive measures of asthenopia are receiving more and more attention.

The research finds that the main causes of the asthenopia are: (1) the theory of free radicals: the eyeball is in a search fixation state for a long time, metabolism of extraocular muscles and ciliary muscles is increased, and metabolic waste products (including oxygen radicals) are generated and accumulated, thereby causing structural damage and functional decline of muscle cells, and studies have been made to show that free radicals may cause and exacerbate various retinal diseases; (2) according to the theory of cell nutrient loss: the recovery time of macula lutea and retina is prolonged because the cell is excessively lost and the required nutrient substances are not supplied in time; (3) theory of retinal damage: visible light is focused on retina to generate high oxygen pressure and high condensation light, lipid peroxidation is easy to occur, and products of the lipid peroxidation phagocytose retinal pigment epithelial cells to cause retina damage; (4) theory of retinal cell senescence: the retinal pigment epithelium cell ages, causing the eye to age, and further causing age-related eye diseases such as the decrease of the optical density of macular pigment.

In addition, the expert studies that blue light can penetrate through crystalline lens and reach retina directly, causing optical damage to the retina; the crystalline lens of teenagers and children is clearer and more transparent than that of adults, and belongs to the vulnerable group. Blue light generally exists in light emitted by tricolor lamps, computer screens, smart phones and the like, especially short-wave blue light (400 nm-500 nm) with irregular frequency has extremely high energy, and retina can generate free radicals after being irradiated for a long time, and the free radicals can cause retina pigment epithelial cell decay, thereby causing various ophthalmic diseases such as retinopathy and the like.

At present, the existing eye care varieties on the market are various, but the defects that the contained components are non-natural nutrient sources, the components are easy to oxidize, the effect of relieving visual fatigue is not obvious and the like are overcome. In addition, the product has single dosage form, and is suitable for treating single diseases such as: the external products mainly take drops and lotion as main materials, and the oral products are mostly tablets or capsules; the product suitable for treating the single disease of dry eye accounts for 55 percent of the market share, and the product suitable for treating the single disease of red eye accounts for 25 percent of the market share.

Disclosure of Invention

Problems to be solved by the invention

The invention provides a composition for relieving visual fatigue, which is prepared by combining medicinal and edible medicinal materials with new food raw materials, is natural and healthy, has obvious antioxidant activity, can effectively relieve visual fatigue and solves the problem that the existing product only aims at improving single diseases.

Further, the invention also provides a preparation method of the composition for relieving the asthenopia.

Furthermore, the invention also provides a preparation containing the composition for relieving the asthenopia, which has various dosage forms, is convenient to eat and is easy to carry.

Further, the invention also provides application of the composition or preparation for relieving asthenopia in preparing eye function foods.

Means for solving the problems

According to the invention, through raw material optimization, medicinal and edible medicinal materials and new food raw materials are combined, a novel asthenopia relieving composition which is natural and healthy, has obvious antioxidant activity, can effectively relieve asthenopia and is suitable for improvement of various diseases is screened, and meanwhile, the asthenopia relieving composition is prepared into various preparations, is convenient to eat and easy to carry, so that the problems can be solved.

Specifically, the method comprises the following steps:

[1] the invention provides a composition for relieving visual fatigue, which comprises the following components: 1-5 parts of medlar powder, 0-5 parts of cassia seed powder, 0-5 parts of chrysanthemum powder, 0-5 parts of lutein substances, 0-5 parts of zeaxanthin, 0-1 part of biological food preservative, 10-50 parts of premix and 20-100 parts of water;

wherein the premix comprises the following components: by weight, 10-50 parts of anthocyanin substances, 0-5 parts of natural carotene and 0-20 parts of prebiotics.

[2] The composition for relieving asthenopia according to the item [1], by weight, 2-4 parts of medlar powder, 0.1-1 part of cassia seed powder, 0.1-1 part of chrysanthemum powder, 0.4-1.5 parts of lutein substances, 0.01-1 part of zeaxanthin, 0-0.1 part of biological food preservative, 25-30 parts of premix and 50-100 parts of water;

wherein the premix comprises the following components: 20-25 parts of anthocyanin substances, 0-1 part of natural carotene and 1-10 parts of prebiotics.

[3] The composition for relieving asthenopia according to [1] or [2], wherein the fructus Lycii powder is a powder sieved with an 80-mesh sieve.

[4] The asthenopia relieving composition according to any one of [1] to [3], wherein the semen Cassiae powder is a powder sieved with an 80-mesh sieve.

[5] The asthenopia relieving composition according to any one of [1] to [4], wherein the chrysanthemum powder is 80-mesh sieved powder.

[6] The asthenopia relieving composition according to any one of [1] to [5], wherein the xanthophyll-based substance comprises one or a combination of two or more of xanthophyll, xanthophyll ester microcapsule powder and marigold extract.

[7] The asthenopia relieving composition according to any one of [1] to [6], wherein the xanthophyll substance is xanthophyll ester microcapsule powder.

[8] According to the composition for relieving asthenopia as described in [6] or [7], at least 95% by weight of the lutein ester microcapsule powder has a particle size of 152 μm or less.

[9] The asthenopia relieving composition according to any one of [1] to [8], wherein at least 95% by weight of the zeaxanthin has a particle size of 152 μm or less.

[10] The asthenopia relieving composition according to any one of [1] to [9], wherein the anthocyanins comprise one or a combination of more than two of aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice, blueberry powder, grapefruit concentrated juice, grapefruit powder, elderberry concentrated juice, elderberry powder, pomegranate concentrated juice and pomegranate fruit juice powder.

[11] The asthenopia relieving composition according to any one of [1] to [10], wherein the anthocyanin substances are selected from one or a combination of more than two of aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice and blueberry powder.

[12] The composition for relieving asthenopia according to [10] or [11], wherein the Aronia melanocarpa powder and the blueberry powder are both powders sieved by a 80-mesh sieve.

[13] The asthenopia relieving composition according to any one of [1] to [12], wherein the prebiotics comprise one or more than two of fructo-oligosaccharide, raffinose, isomalto-oligosaccharide and xylo-oligosaccharide.

[14] The asthenopia relieving composition according to any one of [1] to [13], wherein the prebiotic is fructo-oligosaccharide.

[15] The composition for relieving asthenopia according to any one of [1] to [14], wherein the biological food preservative comprises one or a combination of more than two of nisin, natamycin and monascin.

[16] The asthenopia relieving composition according to any one of [1] to [15], wherein the biological food preservative is nisin.

[17] The present invention also provides a method for preparing the asthenopia relieving composition according to any one of [1] to [16], comprising the steps of:

mixing the anthocyanin substances, optional natural carotene and prebiotics according to the formula ratio to obtain a premix;

mixing the water, the premix, the medlar powder and optional cassia seed powder, chrysanthemum flower powder, xanthophyll substances, zeaxanthin and biological food preservatives according to the formula amount to obtain the composition for relieving the asthenopia.

[18] The invention also provides a preparation for relieving visual fatigue, which comprises the preparation composition for relieving visual fatigue according to any one of the items [1] to [16], and at least one auxiliary material acceptable in bromatology.

[19] The asthenopia relieving preparation according to [18], wherein the dietetically acceptable auxiliary comprises animal glue and vegetable glue.

[20] The preparation for relieving asthenopia according to [19], wherein the animal gum comprises one or a combination of two or more of fish gelatin, bone gum and hide gelatin, and the vegetable gum comprises one or a combination of two or more of acacia gum, sesbania gum, tragacanth gum, pullulan and pectin.

[21] The asthenopia-relieving preparation according to any one of [18] to [20], which comprises a liquid beverage, a solid beverage, a jelly and a gel candy.

[22] The invention also provides the use of the asthenopia relieving composition according to any one of [1] to [16] or the asthenopia relieving preparation according to any one of [18] to [21] in the preparation of an eye function food for relieving general discomfort caused by ocular swelling, ophthalmalgia, photophobia, blurred vision, dry eye, foreign body sensation in eyes, lacrimation, congestion of eyes and visual function reduction.

ADVANTAGEOUS EFFECTS OF INVENTION

The composition for relieving the asthenopia provided by the invention is a combination of various natural medicinal and edible medicinal materials and new food raw materials, is safe, natural and healthy, is not added, and has better flavor and mouthfeel; the antioxidant activity is remarkable, and the stability is good; the active ingredient content is high, the dosage is small, and the effect of relieving visual fatigue is obvious; has low calorie, is not easy to cause GI value increase, and is suitable for people with weight loss and diabetes.

Furthermore, the extract used in the preparation method of the composition for relieving the asthenopia provided by the invention is a high-quality genuine raw material, the comprehensive standardization and standardized quality control are carried out from a raw material base to production circulation, and the water-soluble components in the extract can be well reserved through low-temperature water extraction and spray drying, and the safety of the product is also ensured.

Furthermore, the preparation for relieving the visual fatigue provided by the invention has the advantages of richer dosage form, convenience for eating and easiness for carrying.

Drawings

In order to more clearly illustrate the detailed description of the invention or the technical solutions in the prior art, the drawings that are needed in the detailed description or the prior art description will be briefly described below. The drawings in the following description are some embodiments of the invention, and it is obvious to those skilled in the art that other drawings can be obtained from the drawings without inventive effort.

FIG. 1 is a graph showing the effect of a test sample on the amount of lacrimal fluid secretion in a dry eye rat;

FIG. 2 is a graph showing the effect of a test sample on tear film break-up time in a dry eye rat;

FIG. 3 is a graph showing the effect of test samples on SOD in retinas of the test groups;

figure 4 is a graph of the effect of test samples on MDA in retinas from the test diet.

Detailed Description

The present invention will be described in detail below. The technical features described below are explained based on typical embodiments and specific examples of the present invention, but the present invention is not limited to these embodiments and specific examples. It should be noted that:

the term "eye functional food" in the context of the present invention means, unless otherwise specified, a functional food having the functions of protecting eyes, improving discomfort of eyes, and relieving and/or improving asthenopia.

In the present specification, the numerical range represented by the expression "numerical value a to numerical value B" means a range including the end points of numerical values a and B.

In the present specification, the meaning of "may" includes both the meaning of performing a certain process and the meaning of not performing a certain process.

In this specification, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

In the present specification, reference to "some particular/preferred embodiments," "other particular/preferred embodiments," "embodiments," and the like, means that a particular element (e.g., feature, structure, property, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the described elements may be combined in any suitable manner in the various embodiments.

< first aspect >

The invention provides a composition for relieving visual fatigue, which comprises the following components: 1-5 parts of medlar powder, 0-5 parts of cassia seed powder, 0-5 parts of chrysanthemum powder, 0-5 parts of lutein substances, 0-5 parts of zeaxanthin, 0-1 part of biological food preservative, 10-50 parts of premix and 20-100 parts of water;

wherein the premix comprises the following components: by weight, the anthocyanin substance is 10 to 50 parts, the natural carotene is 0 to 5 parts and the prebiotics is 0 to 20 parts.

According to the composition for relieving asthenopia, the wolfberry fruit powder, the cassia seed powder, the chrysanthemum flower powder and the like are natural medicinal and edible medicinal material extracts, and the lutein substances, the zeaxanthin and the like are new food raw materials, are medicinal and edible, are safe, natural and healthy, and are not added; meanwhile, the components also have antioxidant activity, and can improve the stability of the composition. Moreover, the anthocyanin substances can adjust the flavor and are suitable for the taste of modern people; the natural carotene can promote the generation of internal photochromic pigment and can be converted into vitamin A according to the needs of human body; the prebiotics cannot be directly digested and absorbed by human body, can only be absorbed and utilized by intestinal bacteria, has low calorie, cannot cause obesity, and is a good sweetener suitable for diabetic patients; the biological food preservative has the characteristics of high efficiency and no toxicity, can be degraded by chymotrypsin in a human body, and does not remain in the human body. The invention can effectively relieve the visual fatigue through the synergy of the components.

The invention optimizes the proportion of the components and screens out the composition with better asthenopia relieving effect. In some preferred embodiments of the present invention, the asthenopia relieving composition comprises the following components: the food preservative comprises, by weight, 2-4 parts of wolfberry powder, 0.1-1 part of cassia seed powder, 0.1-1 part of chrysanthemum powder, 0.4-1.5 parts of lutein substances, 0.01-1 part of zeaxanthin, 0-0.1 part of biological food preservative, 25-30 parts of premix and 50-100 parts of water;

wherein the premix comprises the following components: 20 to 25 portions of anthocyanin substances, 0 to 1 portion of natural carotene and 1 to 10 portions of prebiotics. The components are matched in a coordinated ratio, the content of active ingredients is high, and various asthenopia symptoms can be relieved; when a certain component is missing or its weight part is reduced, the above technical effect is weakened.

In some more preferred embodiments of the invention, the asthenopia relieving composition comprises the following components: the food preservative comprises, by weight, 2-4 parts of wolfberry powder, 0.1-1 part of cassia seed powder, 0.1-1 part of chrysanthemum powder, 0.4-1.5 parts of lutein substances, 0.01-1 part of zeaxanthin, 0-0.1 part of biological food preservative, 25-30 parts of premix and 50-100 parts of water;

The composition for relieving asthenopia has the advantages of good component stability, high active ingredient content, no solvent residue, high safety, and definite curative effect, and can avoid the use of components containing microorganisms, easily causing allergy to human, or having obvious genetic toxicity.

In some more preferred embodiments of the invention, the asthenopia relieving composition comprises the following components: the food comprises, by weight, 2.53 parts of wolfberry powder, 0.28 part of cassia seed powder, 0.23 part of chrysanthemum powder, 0.46 part of lutein substances, 0.023 part of zeaxanthin, 0.016 part of biological food preservatives, 26.12 parts of premix and 70.357 parts of water;

wherein the premix comprises the following components: according to parts by weight, 20.9 parts of anthocyanin substances, 0.024 part of natural carotene and 5.18 parts of prebiotics.

[ wolfberry powder ]

The medlar powder of the invention is medlar extract. The medlar contains medlar polysaccharide, carotenoid, alkaloid, medlar pigment, vitamin and trace elements, and is recorded in Ben Cao Bei Yao (herbal reservation): fructus Lycii has effects of dispelling wind and improving eyesight. The lycium barbarum polysaccharide and the carotenoid component can effectively prevent retinal pigment epithelial cells from being oxidized and inflammatory injury, and can provide certain help for preventing and treating glaucoma. The amide alkaloid is the alkaloid with the highest content in the medlar, and has obvious antioxidant activity; quaternary ammonium alkaloids (such as betaine) can inhibit retinal neovascularization in diabetic patients. The Chinese wolfberry pigment is various color development substances existing in Chinese wolfberry berries, is an important physiological active ingredient of Chinese wolfberry seeds, has the effects of improving the human body immunity, preventing and inhibiting tumors, preventing atherosclerosis and the like, and mainly comprises beta-carotene, lutein and other colored substances; wherein, the beta-carotene is the main active component of the medlar pigment, and has important physiological functions of resisting oxidation, serving as a synthetic precursor of vitamin A and the like; zeaxanthin is dihydroxy derivative of beta-carotene, and can prevent macular hypopigmentation and drusen accumulation in the elderly; lutein is a vitamin necessary for protecting eyesight, and can absorb harmful light such as blue light. Vitamin B1 and vitamin C in fructus Lycii have effects of nourishing liver and kidney, replenishing vital essence, improving eyesight, and effectively improving blurred vision, dizziness, etc.

As for the content of the above-mentioned wolfberry powder, in some specific embodiments of the present invention, the wolfberry powder may be 1 to 5 parts by weight, and exemplarily may be 1 part, 2 parts, 2.53 parts, 3 parts, 3.5 parts, 4 parts, 5 parts, etc., preferably 2 to 4 parts, and more preferably 2.53 parts.

The particle size of the above-mentioned wolfberry powder is not particularly limited in the present invention, and can be determined by those skilled in the art according to the actual needs. In some specific embodiments of the invention, the wolfberry powder is a powder which is sieved by a 80-mesh sieve, is easy to dissolve in water and is beneficial to absorption of a body. If the subsequent granulation is needed, the fluidization granulation is also convenient.

[ Cassia seed powder ]

The cassia seed powder is a cassia seed extract. The cassia seed is a traditional Chinese medicine food material, and is recorded in a Chinese medicine dictionary: semen Cassiae contains chrysophanol, emodin, obtusin, aurantio-obtusin and vitamin A, and has effects of clearing liver-fire, improving eyesight, conjunctival congestion, relieving pain, and dim and unclear vision. The semen Cassiae extract has good antioxidant effect, and can protect eye lens against oxidative damage. The formation of cataract is related to the excess of glucose in the crystalline lens, and the cassia seed can increase the activity of Lactate Dehydrogenase (LDH) in eye tissues, so that the glucose amount in the crystalline lens can be reduced through glycolysis, and the cassia seed has a favorable effect on preventing and treating cataract.

With respect to the amount of the above-mentioned cassia seed powder, in some specific embodiments of the present invention, the cassia seed powder is 0 to 5 parts by weight, and illustratively, may be 0,0.1 part, 0.2 part, 0.28 part, 0.35 part, 0.5 part, 0.75 part, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, etc., preferably 0.1 to 1 part, and more preferably 0.28 part.

The particle size of the cassia seed powder is not particularly limited, and can be determined by those skilled in the art according to actual needs. In some specific embodiments of the invention, the cassia seed powder is powder sieved by a 80-mesh sieve, is easy to dissolve in water and is beneficial to body absorption. If the subsequent granulation is needed, the fluidization granulation is also convenient.

[ Chrysanthemum powder ]

The chrysanthemum powder is an extract of chrysanthemum, has the effects of nourishing liver, improving eyesight and relieving pressure, and can effectively relieve the symptoms of dry eyes caused by hyperactivity of liver fire and overuse of eyes. The "Yin Hai Jing Wei" records: chrysanthemum, with slightly cold nature and sweet and bitter taste, enters liver meridian, clears head wind, releases exterior, improves eyesight and removes nebula; modern researches find that chrysanthemum has certain effects of preventing and treating eye injury caused by light pollution, such as eye redness and swelling. ' 20319said medicine has the functions of improving eyesight, reducing swelling, promoting blood circulation and relieving eye fatigue, etc.. The Cixi Guang Jing Yi Fang Chong (a prescription of Cixi Ling) records: the eyesight improving and life prolonging pill consists of frosted mulberry leaf and chrysanthemum, has the functions of calming liver and improving eyesight, clearing heat and dispelling wind, and is mainly used for treating wind-heat headache, conjunctival congestion and dim eyes. The flavonoids in the chrysanthemum can be main functional components for improving eyesight, the acting targets are mainly crystalline lens and retina, and the effects of resisting oxidation, inflammation and apoptosis can protect retinal pigment epithelial cells from various damages, promote cell proliferation, reduce apoptosis and regulate the levels of various apoptosis proteins or mRNA.

With respect to the content of the chrysanthemum powder, in some specific embodiments of the present invention, the chrysanthemum powder is 0 to 5 parts, and illustratively, may be 0,0.1 part, 0.23 part, 0.35 part, 0.5 part, 0.75 part, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, etc., preferably 0.1 to 1 part, and more preferably 0.23 part, by weight.

The particle size of the chrysanthemum powder is not particularly limited, and can be determined by those skilled in the art according to actual needs. In some specific embodiments of the invention, the chrysanthemum powder is 80-mesh powder, is easy to dissolve in water and is beneficial to absorption by organisms. If the subsequent granulation is needed, the fluidization granulation is also convenient.

[ xanthophylls ]

Lutein is the main pigment component of human retina, and can protect eyes from light damage, delay aging of eyes and prevent pathological changes, promote regeneration of Rhodopsin (Rhodopsin) in retinal cells, prevent severe myopia and retinal detachment, improve eyesight and protect eyesight. Lutein acts as an antioxidant and photoprotecting on the primary physiological function of the eye. Optic nerve can not be regenerated and is very easy to be damaged by harmful free radicals, and xanthophyll has antioxidation effect to inhibit the formation of harmful free radicals; the lutein can absorb a large amount of blue light, and can reduce the damage of oxidative stress on eyeballs, namely, the lutein has resistance to the oxidation induced by ultraviolet rays in the macular area of the retina. The light passes through the zone of highest concentration of lutein before reaching the sensitive cells of the retina, and this damage can be minimized if the macular area of the retina is rich in lutein. Besides, the lutein can also improve macular pigment, promote macular development and effectively prevent vision loss and blindness caused by retinal macular degeneration.

In some embodiments of the invention, the xanthophylls include one or a combination of more than two of lutein, lutein ester microcapsule powder and marigold extract, both of which are rich in lutein.

In some preferred embodiments of the present invention, the xanthophylls are lutein ester microencapsulated powders. The lutein ester microcapsule powder is a lutein ester microcapsule structure and has strong tolerance stability to light, heat, oxygen and pH; and sodium ascorbate, oligomeric maltose, etc. are added, so that safety is high. The lutein ester is a new food raw material, and is decomposed into free lutein after being absorbed by human body.

With respect to the above-mentioned xanthophylls content, in some specific embodiments of the present invention, the xanthophylls are 0 to 5 parts by weight, and when the xanthophylls content is more than 5 parts by weight, there may be a safety risk. Illustratively, the xanthophyll-based substance content may be 0,0.2 parts, 0.46 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.5 parts, 2 parts, 3 parts, 4 parts, 5 parts, etc., preferably 0.4 to 1.5 parts, more preferably 0.46 parts.

The particle size of the above lutein ester microcapsule powder is not particularly limited, and can be determined by those skilled in the art according to actual needs. In some preferred embodiments of the invention, at least 95 wt% or more of the lutein ester microcapsule powder has a particle size of 152 μm or less, which is favorable for efficient absorption in small intestine.

[ zeaxanthin ]

Zeaxanthin, also known as (3R, 3' R) -dihydroxy- β -carotene, is the only 2 carotenoid found in the lens of the human eye. As a strong antioxidant, it can quench singlet oxygen and the triplet state of photosensitizers, scavenge damaging oxygen free radicals, prevent membrane lipid peroxidation, reduce lipofuscin formation, prevent cataract formation; moreover, zeaxanthin can specifically absorb the most damaging blue light rays to the retina, thereby protecting the cone cells in the center of the retina, and is a very effective blue light filter.

In some preferred embodiments of the present invention, zeaxanthin is microencapsulated to improve the stability of the effective ingredients and ensure that it is not damaged in the digestive tract.

With respect to the above-mentioned zeaxanthin content, in some specific embodiments of the invention, the zeaxanthin is 0 to 5 parts by weight, and when the zeaxanthin content is more than 5 parts by weight, there may be a safety risk. Illustratively, the zeaxanthin content may be 0,0.01 parts, 0.023 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.08 parts, 0.1 parts, 0.5 parts, 1 part, 2.5 parts, 5 parts, etc., preferably 0.01 to 0.1 parts, more preferably 0.023 parts.

With respect to the particle size of the zeaxanthin described above, in some preferred embodiments of the invention, at least ≧ 95% by weight of the zeaxanthin has a particle size of ≦ 152 μm, which facilitates its efficient absorption in the small intestine.

Biological food preservative

The biological food preservative refers to a high-efficiency preservative which is obtained from organisms through biological culture, extraction and separation technologies and has the effect of inhibiting and killing microorganisms. In some specific embodiments of the present invention, the biological food preservative comprises one or a combination of two or more of nisin, natamycin and monascin.

In some preferred embodiments of the invention, the biological food preservative is nisin. The nisin is stable and high in safety, can be degraded by a human body after being ingested, does not remain in the body, does not produce drug-resistant pathogenic bacteria, and does not have cross resistance with other antibiotics.

The content of nisin should meet the regulations of the national standard for food additive use for food safety GB 2760-2014 (the maximum use amount in beverage products is 0.2g/kg, wherein the use amount of solid beverages is adjusted according to the brewing multiple). In some specific embodiments of the present invention, nisin is present in an amount of 0 to 1 part by weight, illustratively 0,0.01 part, 0.014 part, 0.016 part, 0.018 part, 0.025 part, 0.05 part, 0.1 part, 0.5 part, 1 part, and the like, preferably 0 to 0.1 part, more preferably 0 to 0.018 part, and even more preferably 0.016 part.

[ premix ]

The premix is prepared by mixing anthocyanins and optionally natural carotene and prebiotics.

In some preferred embodiments of the invention, the premix comprises anthocyanins, natural carotene and prebiotics.

The premix may be contained in an amount of 10 to 50 parts, for example, 10 parts, 15 parts, 20 parts, 25 parts, 26.12 parts, 28 parts, 35 parts, 40 parts, 45 parts, 50 parts, etc., preferably 25 to 30 parts, and more preferably 26.12 parts.

Anthocyanidin substance

The anthocyanin is a water-soluble natural plant pigment, is safe and nontoxic, and can be rapidly discharged with urine and bile when being taken too much. The anthocyanidin has effects of activating retina, enhancing vision, and preventing asthenopia; anthocyanins can also be used for preventing diabetic cataract postoperative complications; the anthocyanin can also relieve the damage of free radicals to the crystalline lens of eyes and relieve eye fatigue and damage caused by long-time operation of a computer or driving and the like; the anthocyanidin can promote the resynthesis of rhodopsin in dark, improve the light sensitivity of retina, prevent severe myopia and retinal detachment, improve retinal pigment degeneration and amblyopia, prevent visual deterioration, and improve vision; the anthocyanin can also strengthen the walls of the capillaries of the eyes, promote the blood circulation of the capillaries, maintain normal eyeball pressure, effectively inhibit enzymes which damage eye cells and relieve various eye diseases.

The anthocyanin-based substance of the present invention is not particularly limited, and can be determined by those skilled in the art according to the actual need. In some specific embodiments of the present invention, the anthocyanins comprises one or more of aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice, blueberry powder, grapefruit concentrated juice, grapefruit powder, elderberry concentrated juice, elderberry powder, red pomegranate concentrated juice and red pomegranate juice powder, and the anthocyanins or fruit powder is rich in anthocyanins with high acidity.

With respect to the content of the above-mentioned anthocyanins, in some specific embodiments of the present invention, the content of the anthocyanins is 10 to 50 parts by weight, and exemplarily may be 10 parts, 15 parts, 20 parts, 20.9 parts, 22 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts, 50 parts, etc., preferably 20 to 25 parts, and more preferably 20.9 parts.

In some preferred embodiments of the present invention, the anthocyanins are selected from one or a combination of two or more of the group consisting of aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice and blueberry powder. The aronia melanocarpa fruit, also called aronia melanocarpa, is a new food raw material, contains phenolic substances, vitamins and the like which are necessary to human bodies, particularly contains rich anthocyanin which accounts for 25 percent of the total amount of the phenolic substances, and takes polyphenol as an important secondary metabolite in the fruit, which is called 'seventh nutrient', and has various physiological activation effects; the blueberry is rich in anthocyanin, can promote the regeneration of rhodopsin in retinal cells, protect the microvessels of eyes and improve blood circulation, so that the visual fatigue can be effectively relieved, the vision of people is enhanced, and the effects of preventing myopia and various eye diseases are achieved.

The particle size of the aronia melanocarpa powder and the blueberry powder is not particularly limited, and can be determined by a person skilled in the art according to actual needs. In some more preferred embodiments of the present invention, the particle sizes of the aronia melanocarpa powder and the blueberry powder are both 80-mesh powder, and the aronia melanocarpa powder and the blueberry powder are easily dissolved in water and are beneficial to absorption of the body. If granulation is needed subsequently, fluidization granulation is also facilitated.

In some preferred embodiments of the present invention, the anthocyanins are selected from the group consisting of aronia melanocarpa concentrated juice and blueberry concentrated juice, wherein the aronia melanocarpa concentrated juice is 1-10 parts by weight, and the blueberry concentrated juice is 10-30 parts by weight.

Natural carotene

Natural carotene is a safe and nontoxic natural pigment, is a nutrient substance necessary for human body metabolism, and can be converted into vitamin A only when the body needs the natural carotene. Vitamin A can be converted into rhodopsin required by eyes in vivo, and the rhodopsin participates in visual imaging and dark adaptation and is also an essential nutrient for maintaining the transparency of cornea and the nutrient metabolism of cornea. If vitamin A is deficient, night blindness, corneal dryness, and corneal softening may result.

The specific type of natural carotene used in the present invention is not particularly limited, and can be determined by those skilled in the art according to the actual need. In some embodiments of the invention, the natural carotene may be a carotenoid, carotene or a dunaliella salina extract.

In some preferred embodiments of the present invention, the natural carotene in the present invention is a natural carotene extracted from dunaliella salina as a new resource, and contains α -carotene, γ -carotene and small amounts of other carotenoids in addition to β -carotene. The proper amount of beta-carotene can help to keep the lubrication and transparency of the cornea of the eye, promote the rhodopsin to reach the normal content, protect the fiber part of the eye crystal, make up the dark vision field slow adaptation caused by the lack of vitamin A, can treat night blindness, is a high-efficiency antioxidant for resisting free radicals, has the functions of efficiently quenching singlet oxygen and eliminating free radicals, and prevents cataract; it can also be used for preventing nyctalopia, xerophthalmia, corneal ulcer and keratomalacia.

The content of the natural carotene is in accordance with the regulations of the national standard for food additive use of GB 2760-2014 food safety, and the raw materials can be added into various foods as required, so the content of the carotene is not particularly limited in the invention. In some particular embodiments of the invention, the natural carotene is present in an amount of 0 to 5 parts, illustratively 0,0.01 parts, 0.024 parts, 0.05 parts, 0.1 parts, 1 part, 2 parts, 5 parts, etc., preferably 0 to 1 part, more preferably 0.01 to 0.05 parts, and even more preferably 0.024 parts.

Prebiotics

Prebiotics are dietary supplements that improve host health by selectively stimulating the growth and activity of one or a small number of bacteria in a colony to beneficially affect the host. A successful prebiotic should be one that, when passed through the upper digestive tract, is largely undigested and can be fermented by the gut flora. Most importantly, prebiotics improve the intestinal flora and provide energy and nutrients for the proliferation of probiotics.

The specific type of prebiotics used in the present invention is not particularly limited, and can be determined by those skilled in the art according to the actual need. In some specific embodiments of the invention, the prebiotic comprises one or a combination of two or more of fructooligosaccharide, raffinose, isomaltooligosaccharide, and xylooligosaccharide.

In some preferred embodiments of the invention, the prebiotic is a fructooligosaccharide. Fructo-oligosaccharide is a natural active substance and is known as a new generation additive with the most potential after the age of antibiotics, namely a growth-promoting substance; known as protistan (PPE) in france to maintain gastrointestinal health functions. The fructo-oligosaccharide is not hydrolyzed by enzymes in small intestine of human body, can completely reach colon, can not be directly digested and absorbed by human body, and can only be absorbed and utilized by intestinal bacteria, so that the fructo-oligosaccharide has low calorie, can not cause obesity, and is a good novel sweetener suitable for diabetic patients. Consumption of 15g of fructo-oligosaccharides per day does not significantly affect blood glucose or serum lipid concentrations, while increasing satiety, reducing hunger and expected food intake, and thereby reducing the total caloric value taken during the day. In addition, the fructo-oligosaccharide can promote the absorption of trace elements such as calcium, magnesium and zinc, and improve the bioavailability of the trace elements; has effects in preventing dental caries, improving intestinal microorganisms, reducing serum cholesterol and triglyceride, and promoting absorption of nutrients (especially calcium).

With respect to the above prebiotic content, in some specific embodiments of the present invention, the prebiotic content is 0 to 20 parts, illustratively 0,1 part, 2.5 parts, 5.18 parts, 7.5 parts, 10 parts, 15 parts, 20 parts, etc., preferably 1 to 10 parts, more preferably 5.18 parts, by weight.

More importantly, the components have a synergistic effect:

fructus Lycii powder, semen Cassiae powder and flos Chrysanthemi powder

The composition for relieving asthenopia provided by the invention has the effects of calming the liver, relieving depression, promoting blood circulation, dispelling wind, clearing heat, tonifying liver and kidney, nourishing yin, improving eyesight and the like. The cassia seed and the chrysanthemum have the effects of clearing liver and improving vision, and are mainly used for treating conjunctival congestion and swelling pain, photophobia and photophobia caused by liver channel wind heat or liver fire flaming up, and epiphora induced by wind; semen Cassiae combined with fructus Lycii can nourish liver to improve eyesight, and treat blurred vision due to kidney deficiency.

Fructus Lycii powder, lutein ester microcapsule powder and zeaxanthin

The fructus Lycii contains abundant fructus Lycii polysaccharide, carotenoid, free amino acids, betaine and vitamins B1, B2, E, C, etc. Chua, etc. can detect 18 kinds of carotene from fructus Lycii, and the most content is zeaxanthin dipalmitate, which accounts for about 40% of total carotenoid. Carotenoid extracted from fructus Lycii has certain therapeutic effects in regulating immunity, resisting aging and stress, and especially zeaxanthin and xanthophyll have important effects. Zeaxanthin can effectively relieve retinal pigment epithelial cell apoptosis caused by oxidative stress, thereby effectively preventing age-related macular degeneration (AMD).

Lutein and zeaxanthin are isomers, which can selectively accumulate in the macular area of the eyeball when spreading over the retina area, but the two are concentrated at different positions, zeaxanthin is mainly concentrated in the center of the macular area of the retina, and lutein spreads over the retina. Lutein and zeaxanthin and their common metabolite, meso-zeaxanthin, commonly known as Macular Pigment (MP), prevent damage to the macular area by singlet oxygen produced by ultraviolet light, inhibit free radical generation by quenching singlet oxygen, and protect and prevent the oxidative denaturation of polyunsaturated fatty acids in retinal cells. Zeaxanthin and lutein can prevent oxidation of protein and lipid in eyeball lens, thereby reducing senile cataract. The xanthophyll has antioxidant effect, and can relieve damage of retinal cell caused by strong light irradiation, inhibit oxidative stress injury caused by chronic hyperglycemia, interrupt multiple inflammatory immune reactions caused by oxidative stress, relieve endothelial cell apoptosis, relieve damage of hyperglycemia to ocular fundus blood vessel, etc., and ensure normal retinal function.

Anthocyanins and natural carotene

In the anthocyanin substances, the aronia melanocarpa fruit and the blueberry fruit contain phenol substances, vitamins, proteins and amino acids which are necessary for human bodies, and also contain abundant macroelements and microelements, particularly abundant anthocyanin, and the combination with natural carotene can effectively finish the rapid generation and metabolism of VA in vivo, participate in the promotion of rhodopsin synthesis and regeneration, protect eyesight, promote the microcirculation and prevent degenerative eye diseases.

< second aspect >

The present invention provides a method for preparing a asthenopia relieving composition according to < first aspect >, comprising the steps of:

mixing the water, the premix, the medlar powder and optional cassia seed powder, chrysanthemum flower powder, xanthophyll substances, zeaxanthin and biological food preservatives according to the formula ratio to obtain the composition for relieving the asthenopia.

The extracts of the wolfberry fruit powder, the cassia seed powder, the chrysanthemum powder and the like used in the preparation method are high-quality genuine raw materials, the comprehensive standardization and standardized quality control are carried out from a raw material base to production circulation, the water-soluble components in the extracts can be well reserved through low-temperature water extraction and spray drying, and the safety of the product is ensured.

The sources of the above components are illustrated as follows:

[ wolfberry powder ]

The preparation method of the medlar powder is not particularly limited, and can be determined by a person skilled in the art according to actual needs. In some embodiments of the present invention, the method for preparing wolfberry powder comprises the following steps:

pretreatment: cleaning fructus Lycii, and drying;

extraction: putting the treated barbary wolfberry fruit into an extraction tank, adding water with the amount of 12-14 times of the material amount, heating to 85 +/-5 ℃, and preserving heat for 1-2 hours to obtain a mixed extracting solution;

centrifugal separation: centrifuging the extract by a butterfly centrifuge to obtain a clarified liquid;

and (3) low-temperature concentration: placing the clear solution in a negative pressure concentration tank, carrying out reduced pressure low-temperature concentration, keeping the concentration temperature at 60-70 ℃, and passing the concentrated solution through a 200-mesh screen to obtain a clear concentrated solution;

spray drying: heating the concentrated solution, stirring, feeding the filtrate into a spray drying system, drying, and sieving with 80 mesh sieve to obtain fructus Lycii powder.

[ Cassia seed powder ]

The method for preparing the cassia seed powder is not particularly limited, and can be determined by a person skilled in the art according to actual needs. In some specific embodiments of the present invention, the method for preparing the cassia seed powder comprises the following steps:

pretreatment: washing semen Cassiae, and drying;

extraction: putting the processed cassia seeds into an extraction tank, adding 14-16 times of water, heating to slight boiling, and keeping for 1-2 hours to obtain a mixed extracting solution;

spray drying: heating the concentrated solution, stirring, feeding the filtrate into a spray drying system, drying, and sieving with 80 mesh sieve to obtain semen Cassiae powder.

[ Chrysanthemum powder ]

The preparation method of the chrysanthemum powder is not particularly limited, and can be determined by a person skilled in the art according to actual needs. In some specific embodiments of the present invention, the method for preparing chrysanthemum powder comprises the following steps:

pretreatment: cleaning flos Chrysanthemi, and drying;

extraction: putting the treated chrysanthemum into an extraction tank, adding water with the amount of 20-25 times of the material amount, heating to slightly boil, and keeping for 0.5-1 hour to obtain a mixed extracting solution;

low-temperature concentration: placing the clear solution in a negative pressure concentration tank, carrying out reduced pressure low-temperature concentration, keeping the concentration temperature at 60-70 ℃, and passing the concentrated solution through a 200-mesh screen to obtain a clear concentrated solution;

and (3) spray drying: heating the concentrated solution, stirring, feeding the filtrate into a spray drying system, drying, and sieving with 80 mesh sieve to obtain flos Chrysanthemi powder.

[ xanthophylls ]

In some specific embodiments of the present invention, the lutein-like substance is selected from commercially available lutein ester microcapsule powder, which is available from Daliano Denko corporation, and has a particle size meeting the following requirements: the grain diameter of the lutein ester microcapsule powder with at least more than or equal to 95 percent of weight is less than or equal to 152 mu m.

[ zeaxanthin ]

In some embodiments of the invention, zeaxanthin is available from Shandong Tianyin Biotech, inc. and has a particle size that meets the following requirements: at least 95 wt% of zeaxanthin has a particle size of 152 μm or less.

[ premix ]

The method for preparing the premix is not particularly limited, and can be determined by those skilled in the art according to actual needs. In some embodiments of the invention, the premix is prepared by a method comprising the steps of:

and (3) totally mixing the anthocyanin substances, optional prebiotics and natural carotene in a formula amount in a mixer for 30 minutes to obtain the feed.

Wherein the sources of the components in the premix are as follows:

in some embodiments of the invention, the anthocyanins are selected from blueberry concentrate, available from Fujian Green spring food Co.

In some embodiments of the invention, the anthocyanins are selected from the group consisting of aronia melanocarpa concentrated juice, available from Wuxinuoke technologies, inc.

In some embodiments of the invention, the natural carotene is selected from commercially available 1% natural carotene, purchased from great constant source biotechnology, limited, henan.

< third aspect >

The invention provides an asthenopia relieving preparation, which comprises the asthenopia relieving composition of the < first aspect >, and at least one bromatology acceptable auxiliary material.

In some particular embodiments of the invention, the dietetically acceptable excipients include animal gums and vegetable gums.

In some preferred embodiments of the present invention, animal glues include, but are not limited to, fish glue, gelatin, bone glue, hide glue, and the like; vegetable gums include, but are not limited to, gum arabic, gum sesbania, gum tragacanth, pullulan, pectin and the like. The invention can adopt any one or more of the auxiliary materials and the composition for relieving the visual fatigue to prepare various preparations after mixing.

In some specific embodiments of the invention, the preparation for relieving asthenopia is an eye function food, and comprises various dosage forms such as liquid beverage, solid beverage, jelly and gel candy, and is convenient to eat and easy to carry.

< fourth aspect >

The composition or the preparation for relieving asthenopia has obvious effect of relieving asthenopia, and the composition or the preparation for relieving asthenopia can be suitable for various asthenopia symptoms. In some embodiments of the invention, symptoms of asthenopia include eye swelling, eye pain, photophobia, blurred vision, dry eyes, foreign body sensation in eyes, lacrimation, general malaise caused by congestion of eyes and visual hypofunction. Therefore, the present invention also provides the use of the asthenopia relieving composition according to < first aspect > or the asthenopia relieving preparation according to < third aspect > for preparing an eye function food for relieving general discomfort caused by ocular swelling, ocular pain, photophobia, blurred vision, dry eyes, foreign body sensation in eyes, lacrimation, hyperemia in eyes, and visual hypofunction.

Example 1 liquid beverage for relieving asthenopia

The embodiment provides a preparation method of a liquid beverage for relieving asthenopia, which comprises the following steps:

placing 26.104g of the premix, 2.53g of wolfberry powder, 0.28g of cassia seed powder, 0.23g of chrysanthemum powder, 0.46g of lutein ester micro-capsule powder, 0.023g of zeaxanthin, 0.016g of nisin and 70.357g of water in a storage tank to prepare the composition for relieving asthenopia. Adding quantitative hot water (50 ℃) into a material storage tank, uniformly stirring, emulsifying and homogenizing to ensure complete dissolution, filtering, filling and sterilizing to obtain the liquid beverage.

In this example, the premix included 19.18g of blueberry concentrate, 1.72g of Aronia melanocarpa concentrate, 0.024g of 1% natural carotene, and 5.18g of fructo-oligosaccharides. The pH value of the liquid beverage is adjusted to 4.0-5.0 by utilizing the blueberry concentrated juice and the aronia melanocarpa concentrated juice, and the lutein ester microcapsule powder, the zeaxanthin, the 1% natural carotene and the nisin are relatively stable in the pH environment.

Example 2 gel candy for relieving asthenopia

The embodiment provides a preparation method of a gel candy for relieving asthenopia, which comprises the following steps:

preparing glue solution: mixing 5.5g of fish gelatin and 2.5g of Arabic gum, adding into a proper amount of water for swelling, and then stirring in a water bath at 70-90 ℃ for 0.5-1.0 h to obtain a gelatin solution;

preparing a concentrated solution: placing 26.104g of the premix, 2.53g of medlar powder, 0.28g of cassia seed powder, 0.23g of chrysanthemum powder, 0.46g of lutein ester microcapsule powder, 0.023g of zeaxanthin and 70.373g of water in a storage tank, adding water, decocting at 100-120 ℃, and stirring to obtain a concentrated solution;

casting a mold: mixing the glue solution and the concentrated solution, heating until the mixed system is uniform to obtain a mixed solution, pouring the mixed solution into a mold while the mixed solution is hot, casting the mold, and cooling to obtain the soft candy.

In this embodiment, the fish glue and the gum arabic may also be other types of animal glue or vegetable glue provided by the present invention, respectively. The animal gums of the present invention include, but are not limited to, fish gum, gelatin, bone gum, hide gum, and the like, and the vegetable gums include, but are not limited to, gum arabic, sesbania gum, tragacanth gum, pullulan, pectin, and the like.

Example 3 jelly for relieving asthenopia

The embodiment provides a preparation method of jelly for relieving asthenopia, which comprises the following steps:

preparation of a colloid mixture: mixing 5.5g of pectin and 2.5g of Arabic gum, adding a proper amount of water, and heating in a water bath at 85-100 ℃ for 5-15 min to obtain a colloid mixture;

preparing the jelly: and mixing the colloid mixture and the concentrated solution until the mixed system is uniform to obtain a pre-jelly liquid, sterilizing the pre-jelly liquid, and cooling to obtain the jelly.

In this embodiment, pectin and gum arabic may also be independently replaced with sesbania gum, tragacanth gum, and pullulan.

Example 4 solid beverage for relieving asthenopia

The embodiment provides a preparation method of a solid beverage for relieving asthenopia, which comprises the following steps:

placing 19.18g of blueberry powder, 1.72g of aronia melanocarpa powder, 5.18g of fructo-oligosaccharide, 2.53g of medlar powder, 0.46g of lutein ester micro-capsule powder, 0.024g of natural carotene, 0.28g of cassia seed powder, 0.23g of chrysanthemum powder, 0.023g of zeaxanthin and/or 0.016g of nisin in a storage tank for mixing for 10min. The water is used as an adhesive, the mixture is fluidized and granulated by fluidized bed granulating equipment, intermittent sampling and observation are carried out, corresponding adjustment is carried out according to the condition of granules, and the water content is controlled to be less than or equal to 6.0 percent. Sieving the dried mixed granules, and collecting granules with a granularity of 40-80 meshes to obtain the solid beverage.

The procedure was as in example 1, adjusted according to the recipe in Table 1 to form examples 5-10, respectively.

TABLE 1 formulation of the compositions in the examples

Test examples

Test example 1 safety Observation index

1. Experimental animals: healthy male SD rats, 10, weighing 200 + -20 g. Before the rat experiment, rats of the same age of the same day are selected to be fed for 2 weeks under the experimental conditions in the animal room environment, the temperature is 20-25 ℃, and the relative humidity is 40-70%.

2. Grouping and administration: 10 rats of 8 weeks old are selected and randomly divided into a test feeding group and a control group, the liquid beverage for relieving the asthenopia in the embodiment 1 is used for intragastric administration and medicine feeding in a fixed time period every day, the intake is converted into 40 g/day according to the recommendation of a human body, the intragastric administration amount is 0.67mL/200g of body weight (the product density is approximately equal to 1), the control group is filled with drinking water with the same volume, and the intragastric administration is continuously carried out for 15 days.

3. The evaluation method comprises the following steps: before and after the experiment, the conventional and biochemical indexes of the food intake, the body weight and the blood of the rat are inspected. (1) Diet = dehumidified feed weight-remaining feed weight, feed weight was weighed with electronic scale. (2) Weight gain = post-test body weight-initial body weight, the weights of the rats before and after the test are weighed by an electronic scale, and the weight of the rat before the test is taken as the initial body weight.

4. Diet amount and body weight

TABLE 2 influence of the test samples on the food consumption and body weight of rats before and after feeding test

Item	Test food group	Control group
			Food consumption (m/g)	26.60±2.51	25.83±3.14
Weight gain (m/g)	2.37±0.31	2.51±0.32

The food consumption and body weight of the test group and the control group before and after the experiment are respectively compared, and the results in the table 2 show that the food consumption and the body weight have no significant difference (P is more than 0.05).

5. Routine blood examination

TABLE 3 test results of the test samples on the blood before and after the test of the test group

Item	Before tasting	After tasting
			Red blood cell (. Times.10) ¹² /L)	4.50±0.64	4.50±0.62
White blood cell (× 10) ⁹ /L)	6.92±0.58	6.90±0.62
			Hemoglobin (g/L)	126.80±6.20	128.60±6.37
Platelets (× 10) ⁹ /L)	191.27±5.69	188.27±6.31

The results of the red blood cell, white blood cell, hemoglobin and platelet measurements before and after the experiment of the comparative test group are shown in Table 3, and no significant difference exists (P is more than 0.05).

6. Blood biochemical index test

TABLE 4 Biochemical index test results before and after the test sample is used for the self-test of the test group

Item	Before tasting	After tasting
			Serum Total protein (g/L)	70.10±3.57	75.80±2.30
Serum albumin (g/L)	41.30±1.30	42.40±2.06
			Glutamic-pyruvic transaminase (U/L)	27.80±1.32	26.70±1.77
Glutamic-oxalacetic transaminase (U/L)	26.30±1.64	28.20±1.87
			Creatinine (mu mol/L)	75.80±2.30	73.60±3.17
Urea nitrogen (mmol/L)	5.40±0.45	5.40±0.43
			Total cholesterol (mmol/L)	4.34±0.25	4.51±0.27
Triglyceride (mmol/L)	1.20±0.19	1.21±0.20
			Fasting blood glucose (mmol/L)	4.74±0.17	4.79±0.19

The biochemical index test values before and after the self experiment of the test food group are respectively compared, and the results in the table 4 show that no significant difference exists (P is more than 0.05).

By combining the test results, after the liquid beverage for relieving asthenopia of the embodiment 1 is taken by a test group, the indexes before and after the test group has no significant difference, which shows that the preparation for relieving asthenopia provided by the invention has no potential safety hazard.

Test example 2

1. The tested population: healthy volunteers aged 20-40 years have no basic diseases of ophthalmology, and have long-term use of eyes.

2. Grouping: volunteers were divided into 7 groups of 70 individuals per group on the basis of randomization, control, and double-blindness.

3. The preparation for relieving asthenopia with different concentrations is prepared as follows:

the test groups 1-7 took liquid beverages formulated with the premixes of examples 1, 5-10. The administration time is 60 days continuously. During the test period, the subject stops taking the medicine or other health care products with the function of improving eyesight and keeps normal diet.

4. The relief of asthenopia symptoms in the subjects by the different samples is as follows:

TABLE 5 Effect of test samples on visual fatigue symptoms of subjects

Group of	Sample (I)	Dosage (g)	Number of examples	Is effective	Invalidation	Effective rate (%)
							Test group 1	Example 1	40	70	65	5	93
Test group 2	Example 5	40	70	44	26	63
							Test group 3	Example 6	40	70	43	27	61
Test group 4	Example 7	40	70	47	23	67
							Test group 5	Example 8	40	70	44	26	63
Test group 6	Example 9	40	70	48	22	69
							Test group 7	Example 10	40	70	43	27	61

After the trial of trial group subjects for 60 days, the trial group subjects obviously improve the asthenopia symptoms such as eye swelling, eye pain, photophobia, food blurring, eye dryness, foreign body sensation, lacrimation, general discomfort and the like, and the effective rate is over 60 percent. The liquid beverage for relieving the asthenopia provided by the invention has an obvious effect on relieving the asthenopia, wherein the effective rate of the trial group 1 is the highest and reaches 93%, which shows that the formula in the example 1 is most effective on relieving the asthenopia.

Test example 3

1 materials and objects

1.1 materials

The liquid beverage for relieving asthenopia of example 1 was taken in the test group.

1.2 objects

The subjects 18-65 years old with asthenopia symptoms were selected on a voluntary basis. The subject exclusion criteria were performed by a professional ophthalmologist in accordance with "assessment method of asthenopia-alleviating function" (national food and drug accreditation [2012] "107").

2 method

2.1 grouping

The test subjects were divided into a test group and a control group, each group containing 100 cases, according to the principles of randomization, control, and double-blind. The trial group takes the product for relieving the asthenopia prepared by the invention; control groups received an equal amount of placebo. The administration time is 60 days continuously. During the test period, the subject stops taking the medicine or other health care products with the function of improving vision, and keeps normal diet.

The observation indexes include general conditions, eye use conditions, visual inspection, photopic vision persistence detection, hematuria routine, liver and kidney functions and the like. The above observation indexes are examined once before and after the experiment.

2.2 efficacy determination

(1) Mean integral of symptoms: the visual fatigue symptom judgment method is a semi-quantitative integral method, and the symptom integral before and after the test feeding of the volunteers is calculated.

(2) The vision improvement rate is as follows: the two behaviors are improved after the test eating compared with the prior test eating.

(3) Photopic vision persistence: before and after the test of the test group, compared with the control group, the difference of the photopic vision persistence degree has statistical significance (P is less than 0.05), and the improvement of the average photopic vision persistence degree by more than or equal to 10 percent is effective.

3 results

3.1 comparison of data before and after two sets of test meals

TABLE 6 comparison of two sets of data before and after eating trial

Item	Number of examples	Male/female	Age (year of age)
				Test food group	100	48/52	31.25±8.47
Control group	100	48/52	31.98±8.26

The examination items of the testee before the test are in a normal range, and the index differences of the age, the sex composition, the photopic vision persistence, the binocular vision, the total integral of symptoms, the eye time and the like of the two groups of patients before the test have no statistical significance (P is more than 0.05).

3.2 Change in Total integral of symptoms

TABLE 7 Effect of test samples on the Total score of the subject's symptoms

Group of	Number of examples	After eating trial
			Food testing group	100	4.51±0.36**
Control group	100	6.98±0.23

Before the test food, the total symptom score of the test food group and the control group has no obvious difference. After the test feeding, the total symptom score of the control group is not obviously changed, the total symptom score of the test feeding group is obviously reduced, and the difference has high statistical significance (P is less than 0.01) compared with the difference between the control group and the control group before the test feeding.

3.3 rate of improvement in eyesight

TABLE 8 Effect of test samples on visual acuity improvement in test subjects

Group of	Number of examples	Increase of vision
			Test food group	100	2.27±0.78**
Control group	100	0.57±0.50

Before eating, the eyesight of the eating group is not obviously different from that of the control group. After the test diet, the vision of the control group is not obviously changed, the vision of the test diet group is obviously improved, and compared with the control group, the statistical significance is achieved (P is less than 0.01).

3.4 photopic Vision persistence

TABLE 9 Effect of test samples on subject photopic Retention

Group of	Amplification/(%)
		Test food group	16.03±1.34**
Control group	3.01±1.07

Before the test food, the photopic vision persistence of the test food group and the control group is not obviously different. After the test eating, the photopic vision persistence of the control group is not obviously changed, the photopic vision persistence of the test eating group is obviously improved, and the difference has high statistical significance (P is less than 0.001) compared with that of the control group before the test eating. The result shows that the product for relieving the visual fatigue has a good effect of improving the photopic vision persistence.

Test example 4 Dry eye treatment effect test

The liquid beverages for relieving asthenopia of examples 1 and 5 to 10 were used for the test of the effect of dry eye treatment, and the specific procedures were as follows:

1. experimental animals: healthy male SD rats with the weight of 200 +/-20 g can be used for experiments when the anterior segment and fundus oculi are checked to be free of abnormalities by a slit lamp microscope and a fundoscope. Before the rat experiment, rats of the same age are selected to be fed for 2 weeks under the experimental conditions in the animal room environment, the temperature is 20-25 ℃, and the relative humidity is 40-80%.

2. Modeling of a xerophthalmia rat: the rats were injected with 0.6mg/0.1mL of scopolamine hydrobromide alternately in both lower limbs 4 times a day (8 am and 11 am, 2 pm and 5 pm, respectively, 0.5mL each) and placed in a home-made ventilation apparatus which continuously blows convection wind for 12h a day for 14 days to complete the preparation of the dry eye model, and the ventilation apparatus placed the rats between two fans to blow natural convection wind.

3. Grouping and administration: 90 male rats at 8 weeks of age were selected and randomly divided into 9 groups: blank group, model group, test group 1, test group 2, test group 3, test group 4, test group 5, test group 6 and test group 7. The medicine is fed by filling the medicine liquid components into the stomach at a fixed time period every day, the stomach filling amount is 0.67mL/200g of the body weight (the product density is approximately equal to 1) according to the conversion of 40 g/day recommended by a human body, the blank group and the model group are filled with physiological saline with the same volume, the liquid beverages prepared in the examples 5, 6, 7, 8, 9, 10 and 1 are respectively filled into the test group 1, the test group 2, the test group 3, the test group 4, the test group 5, the test group 6 and the test group 7, and the stomach filling is continuously carried out for 30 days.

4. Measurement of lacrimal secretion: the left/right eyes of the tested animals are randomly selected, and the left and right of each group are respectively half. A test filter paper strip having a length of 35mm × 2mm was bent 3mm from one end, placed in the conjunctival sac of the lower eyelid, and the length of the filter paper strip soaked in 5 minutes was recorded, and the result is shown in FIG. 1.

5. Tear film break-up time determination: the method comprises the steps of selecting untested eyes in a test animal tear secretion amount determination experiment, dripping one drop of 2% fluorescein sodium solution into each eye to close the eyelids, uniformly distributing fluorescein on the surface of the cornea, opening the upper eyelid and the lower eyelid to fully expose the cornea, timing, observing by using a slit lamp cobalt blue light, and recording the time of a first breaking point on the tear film, wherein the result is shown in figure 2.

As can be seen from FIGS. 1 and 2, the significant difference (P < 0.01) between the model-making group and the blank group is observed, and the lacrimal secretion of the rat in the model-making group is reduced and the tear film rupture time is shortened, which indicates the success of model-making. As the experiment is carried out, the lacrimal secretion amount and the tear film rupture time of the model-making rats are recovered, but the difference is still very significant compared with that of a blank group (P < 0.01). The test groups 1-7 have significant difference (P is less than 0.01) to the model building group, which shows that the lacrimal secretion amount and the tear film rupture time are increased after the rat is administrated, and the visual fatigue is favorably relieved.

After the tear film rupture test is finished, the rat is continuously fed for 6 days, the rat is taken for 36 days after gastric lavage, after 16 hours of final administration, the rat is anesthetized by intraperitoneal injection of 0.3mL/100g 10% chloral hydrate solution, abdominal aorta is subjected to blood sampling and killed, retina eyes are quickly removed in an ice environment, water is sucked by filter paper, and the weight is precisely weighed. Adding PBS buffer solution with pH =7.3 to prepare 3% retina homogenate, centrifuging (4 ℃) for 15min at 2500rpm, taking supernatant homogenate, and determining the content of superoxide dismutase (SOD) and Malondialdehyde (MDA) in the retina strictly according to the instruction of an ELISA kit.

The experimental results of each group are shown in fig. 3 and fig. 4, the rats in the blank group are normal rats, compared with the rats in the blank group, the SOD content in retinas of the rats is reduced, the MDA content in the retinas of the rats is increased after modeling, and the difference of the results is very obvious (P is less than 0.01). Compared with the model group, the trial group 1-7 has the advantages that the SOD content in the retina is improved, the MDA content is reduced, and the results have difference (P is less than 0.05), which shows that the antioxidant capacity of the retina of a rat is enhanced after the rat is used with the medicine. The trial group 7 showed that the preparation for relieving asthenopia of example 1 had the best effect, compared with the blank group, in which the SOD content and MDA content in retina were higher and lower than those in the blank group.

It should be noted that, although the technical solutions of the present invention are described by specific examples, those skilled in the art can understand that the present invention should not be limited thereto. Having described embodiments of the present invention, the foregoing description is intended to be exemplary, not exhaustive, and not limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terminology used herein is chosen in order to best explain the principles of the embodiments, the practical application, or improvements made to the technology in the marketplace, or to enable others of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. The composition for relieving the visual fatigue is characterized by comprising the following components: 1-5 parts of medlar powder, 0-5 parts of cassia seed powder, 0-5 parts of chrysanthemum powder, 0-5 parts of lutein substances, 0-5 parts of zeaxanthin, 0-1 part of biological food preservative, 10-50 parts of premix and 20-100 parts of water;

2. The composition for relieving asthenopia according to claim 1, wherein the composition comprises, by weight, 2 to 4 parts of wolfberry fruit powder, 0.1 to 1 part of cassia seed powder, 0.1 to 1 part of chrysanthemum flower powder, 0.4 to 1.5 parts of lutein, 0.01 to 1 part of zeaxanthin, 0 to 0.1 part of biological food preservative, 25 to 30 parts of premix and 50 to 100 parts of water;

wherein the premix comprises the following components: 20-25 parts of anthocyanin substances, 0-1 part of natural carotene and 1-10 parts of prebiotics by weight;

preferably, the wolfberry powder is powder sieved by a sieve of 80 meshes;

preferably, the cassia seed powder is 80-mesh sieved powder;

preferably, the chrysanthemum powder is powder sieved by a sieve of 80 meshes.

3. The asthenopia relieving composition according to claim 1 or 2, wherein the xanthophylls substance comprises one or more of xanthophyll, xanthophyll ester microcapsule powder and marigold extract, preferably xanthophyll ester microcapsule powder;

preferably, at least 95% by weight of the lutein ester microcapsule powder has a particle size of less than or equal to 152 μm.

4. An asthenopia-relieving composition according to any one of claims 1 to 3, wherein at least 95% by weight of the zeaxanthin has a particle size of 152 μm or less.

5. The asthenopia relieving composition of any one of claims 1 to 4, wherein the anthocyanins comprise one or a combination of two or more of Aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice, blueberry powder, grapefruit concentrated juice, grapefruit powder, elderberry concentrated juice, elderberry powder, pomegranate concentrated juice and pomegranate juice powder, preferably one or a combination of two or more of Aronia melanocarpa concentrated juice, aronia melanocarpa powder, blueberry concentrated juice and blueberry powder;

preferably, the aronia melanocarpa powder and the blueberry powder are both powder which is sieved by a sieve with 80 meshes.

6. A composition according to any one of claims 1 to 5, wherein the prebiotic comprises one or a combination of two or more of fructo-oligosaccharide, raffinose, isomalto-oligosaccharide and xylo-oligosaccharide, preferably fructo-oligosaccharide.

7. The composition for relieving visual fatigue as claimed in any one of claims 1 to 6, wherein the biological food preservative comprises one or a combination of more than two of nisin, natamycin and monascin, preferably nisin.

8. A method of preparing a asthenopia-relieving composition according to any one of claims 1 to 7, comprising the steps of:

mixing the anthocyanin substances, optional natural carotene and prebiotics in a formula amount to obtain a premix;

mixing the water, the premix, the wolfberry powder and optional cassia seed powder, chrysanthemum powder, lutein substances, zeaxanthin and biological food preservatives according to the formula amount to obtain the composition for relieving the asthenopia.

9. An asthenopia-relieving preparation comprising the asthenopia-relieving composition according to any one of claims 1 to 7, and at least one bromatologically acceptable auxiliary;

preferably, the asthenopia-relieving preparation comprises liquid beverage, solid beverage, jelly and gel candy.

10. Use of the asthenopia relieving composition according to any one of claims 1 to 7 or the asthenopia relieving preparation according to claim 9 for the preparation of an eye function food for relieving general discomfort caused by ocular swelling, ocular pain, photophobia, blurred vision, dry eye, foreign body sensation in eyes, lacrimation, ocular congestion and visual hypofunction.